KEY FINDINGS
The Asia-Pacific infertility testing & treatment market is projected to develop with a CAGR of 10.90% over the forecasting years. The market growth of the region is essentially driven by factors such as the accessibility to affordable treatments, the accelerated adoption of fertility procedures, and the rise in fertility tourism.
MARKET INSIGHTS
The Asia-Pacific infertility testing & treatment market growth evaluation entails the assessment of South Korea, India, Vietnam, China, Japan, Indonesia, Australia & New Zealand, Thailand, and the rest of the Asia-Pacific. India is anticipated to depict the fastest growth across the region during the estimated period. Rising stress levels, sedentary lifestyles with minimal physical activity, and irregular sleep patterns are widely prevalent in India. As a result, approximately 27.5 million couples actively trying to conceive in the country suffer from infertility, according to several health experts and clinicians. This aspect compels couples to opt for artificial approaches to conception. Moreover, as per the Indian Society of Assisted Reproduction, infertility presently impacts up to 14% of the Indian population, with increased rates observed in urban areas.
In South Korea, infertility treatment, especially IVF, has one of the highest price-quality success ratios across all developed nations globally. Currently, the country has more than 150 clinics as registered IVF centers. In addition to research institutions, these facilities continually aim to improvise the outcome of IVF and their respective success rates by predominantly concentrating on culture conditions for oocyte IVM. Therefore, these factors are anticipated to facilitate the Asia-Pacific infertility testing & treatment market growth during the forecast period.
COMPETITIVE INSIGHTS
Some of the key firms operating in the market are Genea Ltd, Olympus Corporation, Bangkok IVF Center, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. GROWING STRESS AND LIFESTYLE DISORDERS
3.1.2. INCREASED AGE OF CONCEPTION
3.1.3. INCREASING EFFECTIVENESS OF TREATMENTS
3.1.4. RISING GOVERNMENT SUPPORT
3.2. KEY RESTRAINTS
3.2.1. HIGH COST OF TESTING AND TREATMENT
3.2.2. INFERTILITY CONSIDERED A SOCIAL TABOO
3.2.3. POSSIBLE RISKS ASSOCIATED WITH INFERTILITY TREATMENTS
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON INFERTILITY TESTING & TREATMENT MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. KEY BUYING CRITERIA
4.6.1. TREATMENT OPTIONS
4.6.2. QUALITY OF MEDICAL PROCEDURES
4.6.3. PRICE OF TREATMENTS
4.6.4. SHIFT TOWARDS MEDICAL TOURISM
4.6.5. REIMBURSEMENT
4.7. VALUE CHAIN ANALYSIS
4.7.1. RAW MATERIAL PROCUREMENT
4.7.2. MANUFACTURING
4.7.3. SUPPLY LOGISTICS
4.7.4. DISTRIBUTION CHANNELS
4.7.5. END-USERS
5. MARKET BY GENDER
5.1. MALE
5.1.1. MALE INFERTILITY TESTING
5.1.1.1. DNA FRAGMENTATION
5.1.1.2. OXIDATIVE STRESS ANALYSIS
5.1.1.3. SPERM PENETRATION ASSAY
5.1.1.4. COMPUTER-ASSISTED SEMEN ANALYSIS (CASA)
5.1.1.5. SPERM AGGLUTINATION
5.1.1.6. MICROSCOPIC EXAMINATION
5.1.1.7. OTHERS
5.1.2. MALE INFERTILITY TREATMENT
5.1.2.1. MEDICATION
5.1.2.2. ASSISTED REPRODUCTIVE TECHNOLOGY & VARICOCELE SURGERY
5.2. FEMALE
5.2.1. FEMALE INFERTILITY TESTING
5.2.1.1. OVULATION TESTING
5.2.1.2. HYSTEROSALPINGOGRAPHY
5.2.1.3. LAPAROSCOPY
5.2.1.4. TRANSVAGINAL ULTRASOUND
5.2.1.5. OVARIAN RESERVE TESTING
5.2.1.6. HORMONAL LEVEL TESTING
5.2.1.7. OTHERS
5.2.2. FEMALE INFERTILITY TREATMENT
5.2.2.1. IVF WITH ICSI
5.2.2.2. IUI
5.2.2.3. IVF WITHOUT ICSI
5.2.2.4. SURROGACY
5.2.2.5. OTHERS
6. MARKET BY END-USER
6.1. FERTILITY AND SURGICAL CENTERS
6.2. HOSPITALS AND RESEARCH LABORATORIES
6.3. CRYOBANKS
7. GEOGRAPHICAL ANALYSIS
7.1. ASIA-PACIFIC
7.1.1. KEY GROWTH ENABLERS
7.1.2. KEY CHALLENGES
7.1.3. KEY PLAYERS
7.1.4. COUNTRY ANALYSIS
7.1.4.1. CHINA
7.1.4.2. JAPAN
7.1.4.3. INDIA
7.1.4.4. SOUTH KOREA
7.1.4.5. INDONESIA
7.1.4.6. THAILAND
7.1.4.7. VIETNAM
7.1.4.8. AUSTRALIA & NEW ZEALAND
7.1.4.9. REST OF ASIA-PACIFIC
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIC DEVELOPMENTS
8.1.1. MERGERS & ACQUISITIONS
8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
8.1.3. PARTNERSHIP & AGREEMENTS
8.2. COMPANY PROFILES
8.2.1. ADORFEM
8.2.2. BANGKOK IVF CENTER
8.2.3. COOK MEDICAL INC
8.2.4. COOPER SURGICAL
8.2.5. CREATE FERTILITY CENTRE
8.2.6. EMD GROUP (MERCK KGAA)
8.2.7. ENDO INTERNATIONAL PLC
8.2.8. ESCO MEDICAL
8.2.9. FERRING PHARMACEUTICALS
8.2.10. FERTILITY FIRST
8.2.11. FUJIFILM IRVINE SCIENTIFIC
8.2.12. GENEA LTD
8.2.13. HALOTECH DNA
8.2.14. HAMILTON THRONE LTD
8.2.15. IVFTECH
8.2.16. LABOTECT GMBH
8.2.17. OLYMPUS CORPORATION
8.2.18. PROGYNY
8.2.19. THERMO FISHER SCIENTIFIC INC
8.2.20. VITROLIFE AB
1. ADORFEM
2. BANGKOK IVF CENTER
3. COOK MEDICAL INC
4. COOPER SURGICAL
5. CREATE FERTILITY CENTRE
6. EMD GROUP (MERCK KGAA)
7. ENDO INTERNATIONAL PLC
8. ESCO MEDICAL
9. FERRING PHARMACEUTICALS
10. FERTILITY FIRST
11. FUJIFILM IRVINE SCIENTIFIC
12. GENEA LTD
13. HALOTECH DNA
14. HAMILTON THRONE LTD
15. IVFTECH
16. LABOTECT GMBH
17. OLYMPUS CORPORATION
18. PROGYNY
19. THERMO FISHER SCIENTIFIC INC
20. VITROLIFE AB
